Evaxion Biotech Stock (NASDAQ:EVAX)
Previous Close
$0.89
52W Range
$0.85 - $13.61
50D Avg
$1.98
200D Avg
$2.96
Market Cap
$49.78M
Avg Vol (3M)
$61.30K
Beta
-0.23
Div Yield
-
EVAX Company Profile
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. |
| ZVSA | ZyVersa Therapeutics, Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| REVB | Revelation Biosciences, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| VRAX | Virax Biolabs Group Limited |
| ALLR | Allarity Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
| LYEL | Lyell Immunopharma, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |